EkoSonic™ Endovascular System
Efficacy
Ekos has been shown to yield safe and effective results for acute, massive (high risk) and submassive (intermediate risk) PE.
- Reduces RV/LV ratio by more than 23% on average in as little as 2 hours8
- Reduces PA pressures by 28% (at 48 hours)5
- 76% less thrombolytic drug dosage than standard treatment5
- Minimized risk of bleeding1
Study | RV/LV Reduction |
ULTIMA | 23% (24 hours) |
SEATTLE II | 25% (48 hours) |
OPTALYSE | 23-26% (48 hours) |
Safety
Ekos has been shown to have a low risk of bleeding and ICH. [FOOTNOTES NEEDED]
- Low major bleeding rate across studies
- Less than a 1% risk of ICH, two studies with 0 instances of ICH
- 76% less thrombolytic drug dosage than standard treatment
Study | Safety | Total Dose |
ULTIMA | 0% (Major Bleed) | 0 (ICH) | 20mg |
SEATTLE II | 10% (Major Bleed) | 0 (ICH) | 24mg |
OPTALYSE | 3% (Major Bleed) | 1 (ICH) | 4-8mg/12-24mg |